Conference Day Two | Thursday, September 18

9:20 am Chair’s Opening Remarks

Advanced Analytics for Emerging Genome Editing Technologies to Optimize Therapeutic Strategies

9:30 am Development & Analytical Strategies for a Novel Editing Technology

Synopsis

  • Discussing the development and potential applications of CRISPR-based epigenetic editing technologies, including the EPI 321 program
  • Detailing the creation and validation of analytical assays for epigenetic editing, focusing on off-target and on-target analysis, potency assays, and delivery modalities
  • Sharing insights on the journey from initial research and development to achieving IND and CTA approvals, highlighting key challenges and successful strategies

10:00 am Metabolic Engineering & Analytical Development of CAR-NK by CLICK, an Efficient Non-Viral CAR Integration on CISH Locus

  • Howard Wu Co-Founder & Chief Scientific Officer, Full Circles Therapeutics

Synopsis

  • Precise CAR integration at the CISH locus enables targeted, stable, and efficient gene editing
  • Non-viral CLICK platform supports analytical development of off-target profiling and integration efficiency
  • CLICK CAR-NK cells show strong potency, persistence, and reduced exhaustion in vivo

10:30 am Morning Refreshments & Poster Session

Ensuring Tech Transfer to Quality Control & External Teams is Streamlined & Communicated Effectively

11:30 am Expert Discussion: Ensuring Quality Control in Complex Systems for Improved Product Quality

Synopsis

  • Tackling the complexity of CMC manufacturing and QC/QA release for key components, enhancing product quality
  • Addressing the analytical burden of multi-component systems and ensuring high fidelity and uniformity, improving consistency
  • Implementing effective QC strategies to manage supply chain challenges and stability issues, optimizing reliability

12:00 pm Roundtable: Developing a Phase-Appropriate Release & Stability Testing Strategy

Synopsis

  • Choosing appropriate assays and specifications for release and stability testing for each of your CQAs
  • Establishing structure-function studies to supplement regular release panel tests
  • Evolving your testing methods as you progress into and through the clinic

1:00 pm Lunch

Characterizing & Quantifying Heterogeneity in Genome Editing to Ensure Consistency

2:00 pm Expert Discussion: Leveraging Machine Learning & Artificial Intelligence for Improved Precision

  • Kai-Yuan Chen Director - Computational Genomics & Data Science, Scribe Therapeutics

Synopsis

  • Applying machine learning methods to predict off-target effects with greater accuracy, enhancing safety
  • Creating genome editors using advanced AI techniques, improving editing precision
  • Addressing computational challenges in quantifying complex technological landscapes, optimizing data analysis

3:00 pm Regulatory Requirements for sgRNA Characterization in Early & Late Phase CRISPR-Edited TIL Manufacturing

  • Violetta Medik Associate Director - Analytical Development, KSQ Therapeutics, Inc.

Synopsis

  • Utilizing NGS and molecular assays to characterize guide RNA
  • Ensuring comprehensive analysis and phase appropriate implementation of analytical tools to meet regulatory requirements
  • Separating and characterizing impurities within sgRNA lots to maintain eTIL quality

3:30 pm Chair’s Closing Remarks